Interaction of Angiotensin II AT1 Receptors with Purinergic P2X Receptors in Regulating Renal Afferent Arterioles in Angiotensin II-Dependent Hypertension. 2023

Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
Department of Physiology, Hypertension and Renal Center of Excellence, Tulane University School of Medicine, New Orleans, LA 70112, USA.

In angiotensin II (Ang II)-dependent hypertension, Ang II activates angiotensin II type 1 receptors (AT1R) on renal vascular smooth muscle cells, leading to renal vasoconstriction with eventual glomerular and tubular injury and interstitial inflammation. While afferent arteriolar vasoconstriction is initiated by the increased intrarenal levels of Ang II activating AT1R, the progressive increases in arterial pressure stimulate the paracrine secretion of adenosine triphosphate (ATP), leading to the purinergic P2X receptor (P2XR)-mediated constriction of afferent arterioles. Thus, the afferent arteriolar tone is maintained by two powerful systems eliciting the co-existing activation of P2XR and AT1R. This raises the conundrum of how the AT1R and P2XR can both be responsible for most of the increased renal afferent vascular resistance existing in angiotensin-dependent hypertension. Its resolution implies that AT1R and P2XR share common receptor or post receptor signaling mechanisms which converge to maintain renal vasoconstriction in Ang II-dependent hypertension. In this review, we briefly discuss (1) the regulation of renal afferent arterioles in Ang II-dependent hypertension, (2) the interaction of AT1R and P2XR activation in regulating renal afferent arterioles in a setting of hypertension, (3) mechanisms regulating ATP release and effect of angiotensin II on ATP release, and (4) the possible intracellular pathways involved in AT1R and P2XR interactions. Emerging evidence supports the hypothesis that P2X1R, P2X7R, and AT1R actions converge at receptor or post-receptor signaling pathways but that P2XR exerts a dominant influence abrogating the actions of AT1R on renal afferent arterioles in Ang II-dependent hypertension. This finding raises clinical implications for the design of therapeutic interventions that will prevent the impairment of kidney function and subsequent tissue injury.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D001160 Arterioles The smallest divisions of the arteries located between the muscular arteries and the capillaries. Arteriole
D044140 Receptor, Angiotensin, Type 1 An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention. Angiotensin II Type 1 Receptor,Angiotensin Type 1 Receptor,Angiotensin Type 1a Receptor,Angiotensin Type 1b Receptor,Receptor, Angiotensin, Type 1a,Receptor, Angiotensin, Type 1b,Angiotensin AT1 Receptor,Angiotensin AT1a Receptor,Angiotensin AT1b Receptor,Angiotensin II Type 1a Receptor,Angiotensin II Type 1b Receptor,Receptor, Angiotensin II Type 1,Receptor, Angiotensin II Type 1a,Receptor, Angiotensin II Type 1b,AT1 Receptor, Angiotensin,AT1a Receptor, Angiotensin,AT1b Receptor, Angiotensin,Receptor, Angiotensin AT1,Receptor, Angiotensin AT1a,Receptor, Angiotensin AT1b
D058469 Receptors, Purinergic P2X A subclass of purinergic P2 receptors that signal by means of a ligand-gated ion channel. They are comprised of three P2X subunits which can be identical (homotrimeric form) or dissimilar (heterotrimeric form). P2X Purinoceptor,P2X Purinoceptors,P2X Receptors, Purinergic,Purinergic P2X Receptors,Purinoceptor, P2X,Purinoceptors, P2X

Related Publications

Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
June 2020, American journal of physiology. Renal physiology,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
January 2016, Science signaling,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
November 2004, Kidney international,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
September 2005, Hypertension (Dallas, Tex. : 1979),
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
August 2007, Analytical and quantitative cytology and histology,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
December 2008, Journal of the renin-angiotensin-aldosterone system : JRAAS,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
March 1997, The Journal of clinical investigation,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
May 2017, American journal of physiology. Renal physiology,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
December 1994, Kidney international,
Supaporn Kulthinee, and Adis Tasanarong, and Martha Franco, and Luis Gabriel Navar
May 1988, The American journal of physiology,
Copied contents to your clipboard!